Dr. Christopher Michael Polk, MD

Dr. Polk practices at Atrium Health Infectious Disease in Concord, North Carolina.

Dr. Polk's NPI, 1396889333, was assigned on February 15, 2007. Dr. Polk graduated from UTMB Health in 2001. Dr. Polk's North Carolina license number on file is 2007-00866.

Dr. Polk's primary practice is Atrium Health Infectious Disease, at 200 Medical Park NE Dr, Concord, NC 28025 in Cabarrus County. The practice phone is (704) 355-0607.

Dr. Polk's primary practice is Atrium Health Infectious Disease in Concord, North Carolina. Dr. Polk is also affiliated with Atrium Health Carolinas Medical Center. The medical group on file is Atrium Health Cleveland Imaging. Dmand AI also links Dr. Polk to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Polk practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Polk's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Polk is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Polk's licenses on file in 2 states: North Carolina and Maryland.

Dmand AI lists hiv/aids and joint or bone infection among the conditions Dr. Polk treats.

CMS data shows 31 Medicare services from Dr. Polk across 1 procedure code in 2024, all of them office visits, for 23 Medicare patients. Medicare paid $1,679 for them. Every service was in an office.

CMS counts 23 Medicare patients who saw Dr. Polk in 2024. 74% of them have high cholesterol, and 57% have high blood pressure. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Polk's median patient age at 66, with 32% women.

In 2024, Dr. Polk wrote 1,106 Medicare Part D claims for 74 patients. CMS names the drug for 899 of them, across 23 drugs with 11 or more claims each, at $2,836,372 in total drug cost. In 2023, CMS named 1,292 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Polk for performance year 2024, reported through an alternative payment model (APM). Dr. Polk accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 24 papers to Dr. Polk, published from 2018 to 2024. 2022 was the busiest year, with 7. The most frequent topics are Anti-Bacterial Agents, COVID-19 and SARS-CoV-2. Dr. Polk has published most often in AIDS Patient Care STDS. Dr. Polk's most frequent co-authors are Michael Kent Leonard, MD, Mindy Marie Sampson, DO and Catherine L. Passaretti, MD.

CMS Open Payments shows 74 general payments to Dr. Polk from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. ViiV Healthcare Company paid the most, $21,741. It also lists 21 research payments totaling $2,777 from 2017 to 2019.

Dmand AI lists 1 award for Dr. Polk, most recently CMS Stage 1 2012 in 2011.

Dr. Polk graduated from UTMB Health in 2001. Dr. Polk is a member of ACP.

Dr. Polk is in network with 21 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.